285 results on '"Imetelstat"'
Search Results
2. A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
3. Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress)
4. Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
5. Expanded Access for Treatment With Imetelstat
6. A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
7. Obesity-Senescence-Breast Cancer: Clinical Presentation of a Common Unfortunate Cycle
8. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
9. New therapy options for myelodysplastic syndrome—all for all or targeted?
10. Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
11. Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
12. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
13. Raising the bar for lower-risk myelodysplastic syndromes.
14. Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
15. Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.
16. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
17. Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions.
18. Imetelstat (Rytelo) for myelodysplastic syndromes.
19. Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
20. Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
21. A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
22. AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
23. Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts.
24. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
25. Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
26. To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
27. Characterization of In Vitro G-Quadruplex Formation of Imetelstat Telomerase Inhibitor.
28. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.
29. Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
30. Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
31. Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
32. Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
33. Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (ET/PV)
34. Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
35. Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
36. Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
37. Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
38. Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
39. A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
40. An Open Label Treatment Extension Study of AMG 706
41. A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
42. Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat.
43. Geron faces uphill battle at FDA meeting as agency questions benefit-risk profile of imetelstat.
44. Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
45. AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
46. Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
47. [Novel therapies for MDS and future prospects].
48. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.
49. Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors
50. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.